EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 41 / Numéro 5 (Mai 2025) Med Sci (Paris), 41 5 (2025) 434-442 Références
Open Access
Numéro
Med Sci (Paris)
Volume 41, Numéro 5, Mai 2025
Enjeux et objectifs de la psychiatrie de précision
Page(s) 434 - 442
Section La psychiatrie de précision (PEPR PROPSY) : hypothèses et outils
DOI https://doi.org/10.1051/medsci/2025068
Publié en ligne 26 mai 2025
  1. Marder SR, Galderisi S. The current conceptualization of negative symptoms in schizophrenia. World Psychiatry 2017 ; 16 : 14–24. [CrossRef] [PubMed] [Google Scholar]
  2. Guessoum SB, Le Strat Y, Dubertret C, et al. A transnosographic approach of negative symptoms pathophysiology in schizophrenia and depressive disorders. Prog Neuropsychopharmacol Biol Psychiatry 2020 ; 99 : 109862. [CrossRef] [PubMed] [Google Scholar]
  3. Mallet J, Guessoum SB, Tebeka S, et al. Self-evaluation of negative symptoms in adolescent and young adult first psychiatric episodes. Prog Neuropsychopharmacol Biol Psychiatry 2020 ; 103 : 109988. [CrossRef] [PubMed] [Google Scholar]
  4. Schmidt A, Cappucciati M, Radua J, et al. Improving prognostic accuracy in subjects at clinical high risk for psychosis: systematic review of predictive models and meta-analytical sequential testing simulation. Schizophr Bull 2017 ; 43 : 375–88. [PubMed] [Google Scholar]
  5. Bi R, Dong W, Zheng Z, et al. Altered motivation of effortful decision-making for self and others in subthreshold depression. Depress Anxiety 2022 ; 39 : 633–45. [CrossRef] [PubMed] [Google Scholar]
  6. McMakin DL, Olino TM, Porta G, et al. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. J Am Acad Child Adolesc Psychiatry 2012 ; 51 : 404–11. [CrossRef] [PubMed] [Google Scholar]
  7. Strauss GP, Cohen AS. A transdiagnostic review of negative symptom phenomenology and etiology. Schizophr Bull 2017 ; 43 : 712–9. [CrossRef] [PubMed] [Google Scholar]
  8. Fusar-Poli P, Tantardini M, De Simone S, et al. Deconstructing vulnerability for psychosis: meta-analysis of environmental risk factors for psychosis in subjects at ultra high-risk. Eur Psychiatry 2017 ; 40 : 65–75. [CrossRef] [PubMed] [Google Scholar]
  9. Winograd-Gurvich C, Fitzgerald PB, Georgiou-Karistianis N, et al. Negative symptoms: a review of schizophrenia, melancholic depression and Parkinson’s disease. Brain Res Bull 2006 ; 70 : 312–21. [CrossRef] [PubMed] [Google Scholar]
  10. Pignon B, Peyre H, Ayrolles A, et al. Genetic and psychosocial stressors have independent effects on the level of subclinical psychosis: findings from the multinational EU-GEI study. Epidemiol Psychiatr Sci 2022 ; 31 : e68. [CrossRef] [PubMed] [Google Scholar]
  11. Van Os J, Reininghaus U. Psychosis as a transdiagnostic and extended phenotype in the general population. World Psychiatry 2016 ; 15 : 118–24. [CrossRef] [PubMed] [Google Scholar]
  12. Foss-Feig JH, McPartland JC, Anticevic A, Wolf J. Re-conceptualizing ASD within a dimensional framework: positive, negative, and cognitive feature clusters. J Autism Dev Disord 2026 ; 46 : 342–51. [Google Scholar]
  13. Fusar-Poli, P. et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull 2015 ; 41, 892–99. [CrossRef] [PubMed] [Google Scholar]
  14. Strauss GP, Horan WP, Kirkpatrick B, et al. Deconstructing negative symptoms of schizophrenia: Avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J Psychiatr Res 2013 ; 47 : 783–90. [CrossRef] [PubMed] [Google Scholar]
  15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington : APA, 2013. doi : 10.1176/appi.books.9780890425596. [Google Scholar]
  16. Fitzgerald HM, Shepherd J, Bailey H, et al. Treatment goals in schizophrenia: a real-world survey ofpatients, psychiatrists, and Caregivers in the United States, with an analysis of current treatment (long-acting injectable vs oral antipsychotics) and goal selection. Neuropsychiatr Dis Treat 2021 ; 17 : 3215–28. [CrossRef] [Google Scholar]
  17. Dollfus, S. Le déficit motivationnel dans la schizophrénie. Bull Acad Natl Med 2018 ; 202 : 115–26. [Google Scholar]
  18. Vinckier F, Gourion D, Mouchabac S. Anhedonia predicts poor psychosocial functioning: Results from a large cohort of patients treated for major depressive disorder by general practitioners. Eur Psychiatry 2017 ; 44 : 1–8. [CrossRef] [PubMed] [Google Scholar]
  19. Ihler HM, Lyngstad SH, Morch-Johnsen LE, et al. A transdiagnostic approach to negative symptoms: exploring factor structure and negative symptoms in bipolar disorders. Front Psychiatry 2023 ; 14 : 1136097. [CrossRef] [PubMed] [Google Scholar]
  20. Quattrone D, Di Forti M, Gayer-Anderson C, et al. Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. Psychol Med 2019 ; 49 ; 1378–91. [CrossRef] [PubMed] [Google Scholar]
  21. Lindenmayer JP, Bossie CA, Kujawa M, et al. Dimensions of psychosis in patients with bipolar mania as measured by the positive and negative syndrome scale. Psychopathology 2008 ; 41 : 264–70. [CrossRef] [PubMed] [Google Scholar]
  22. Trevisan DA, Foss-Feig JH, Naples AJ, et al. Autism spectrum disorder and schizophrenia are better differentiated by positive symptoms than negative symptoms. Front. Psychiatry 2020 ; 11 : 548. [CrossRef] [Google Scholar]
  23. Kirschner M, Aleman A, Kaiser S. Secondary negative symptoms: a review of mechanisms, assessment and treatment. Schizophr Res 2017 ; 186 : 29–38. [CrossRef] [PubMed] [Google Scholar]
  24. Felger JC, Miller AH. Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front Neuroendocrinol 2012 ; 33 ; 315–27. [CrossRef] [PubMed] [Google Scholar]
  25. Cunnington C, Channon KM. Tetrahydrobiopterin: pleiotropic roles in cardiovascular pathophysiology. Heart Br Card Soc 2010 ; 96 ; 1872–7. [CrossRef] [PubMed] [Google Scholar]
  26. Capuron L, Schroecksnadel S, Féart C, et al. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry 2011 ; 70 ; 175–82. [CrossRef] [PubMed] [Google Scholar]
  27. Zhao H, Zhang H, Liu S, et al. Association of peripheral blood levels of cytokines with autism spectrum disorder: a meta-analysis. Front Psychiatry 2021 ; 12 ; 670200. [CrossRef] [PubMed] [Google Scholar]
  28. Fond G, Mallet J, Urbach M, et al. Adjunctive agents to antipsychotics in schizophrenia: a systematic umbrella review and recommendations for amino acids, hormonal therapies and anti-inflammatory drugs. BMJ Ment Health 2023 ; 26 ; e300771. [CrossRef] [Google Scholar]
  29. Lorentzen R, Nguyen TD, McGirr A, et al. The efficacy of transcranial magnetic stimulation (TMS) for negative symptoms in schizophrenia: a systematic review and meta-analysis. Schizophr Heidelb Ger 2022 ; 8 : 35. [CrossRef] [Google Scholar]
  30. Heeren A, Coussement C, Colon E. La stimulation transcrânienne à courant continu en psychiatrie : vers de nouvelles perspectives d’interventions. Med Sci (Paris) 2016 ; 32 : 752–7. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  31. Fulford D, Marsch LA, Pratap A. Prescription digital therapeutics: an emerging treatment option for negative symptoms in schizophrenia. Biol Psychiatry 2024 ; 96 ; 659–65. [CrossRef] [PubMed] [Google Scholar]
  32. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987 ; 13 : 261–76. [CrossRef] [PubMed] [Google Scholar]
  33. Andreasen NC. The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry 1989 ; 155 : 49–52. [CrossRef] [Google Scholar]
  34. Axelrod BN, Goldman RS, Alphs LD. Validation of the 16-item negative symptom assessment. J Psychiatr Res 1993 ; 27 : 253–8. [CrossRef] [PubMed] [Google Scholar]
  35. Kirkpatrick B, Strauss GP, Nguyen N, et al. The brief negative symptom scale: psychometric properties. Schizophr Bull 2011 ; 37 : 300–5. [CrossRef] [PubMed] [Google Scholar]
  36. Kring AM, Gur RE, Blanchard JJ, et al. The clinical assessment interview for negative symptoms (CAINS): final development and validation. Am J Psychiatry 2013 ; 170 : 165–72. [CrossRef] [PubMed] [Google Scholar]
  37. Llerena K, Park SG, McCarthy JM, et al. The motivation and pleasure scale-self-report (MAP-SR): reliability and validity of a self-report measure of negative symptoms. Compr Psychiatry 2013 ; 54 ; 568–74. [CrossRef] [PubMed] [Google Scholar]
  38. Mach C, Dollfus S. Symptômes négatifs de la schizophrénie : une revue des instruments d’évaluation. L’Encéphale 2016 ; 42 ; 165–71. [Google Scholar]
  39. Ike KGO, de Boer SF, Buwalda, B, et al. Social withdrawal: an initially adaptive behavior that becomes maladaptive when expressed excessively. Neurosci Biobehav Rev 2020 ; 116 : 251–67. [CrossRef] [PubMed] [Google Scholar]
  40. Ebrahimi A, Poursharifi H, Dolatshahi B, et al. The cognitive model of negative symptoms in schizophrenia: a hierarchical component model with PLS-SEM. Front Psychiatry 2021 ; 12 : 707291. [CrossRef] [PubMed] [Google Scholar]
  41. Nikiforuk A, Hołuj M, Kos T, et al. The effects of a 5-HT5A receptor antagonist in a ketamine-based rat model of cognitive dysfunction and the negative symptoms of schizophrenia. Neuropharmacology 2016 ; 105 : 351–60. [CrossRef] [PubMed] [Google Scholar]
  42. Lutsenko RV, Sydorenko AH, Bobyriov VM. Anhedonia at experimental models of chronic stress and its correction. Wiadomosci Lek Wars Pol 2017 ; 196070 : 745–50. [Google Scholar]
  43. Slaney CL, Hales CA, Robinson ESJ. Rat models of reward deficits in psychiatric disorders. Curr Opin Behav Sci 2018 ; 22 ; 136–42. [CrossRef] [PubMed] [Google Scholar]
  44. Bove M, Ike K, Eldering A, et al. The visible burrow system: a behavioral paradigm to assess sociability and social withdrawal in BTBR and C57BL/6J mice strains. Behav Brain Res 2018 ; 344 ; 9–19. [CrossRef] [PubMed] [Google Scholar]
  45. Sahin C, Doostdar N, Neill JC. Towards the development of improved tests for negative symptoms of schizophrenia in a validated animal model. Behav Brain Res 2016 ; 312 ; 93–101. [CrossRef] [PubMed] [Google Scholar]
  46. Millan M.J. Le récepteur dopaminergique D3 : nouvelle cible pour un traitement amélioré de la schizophrénie. Med Sci (Paris) 2005 ; 21 : 434–42. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.